Literature DB >> 31576545

Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.

Jacqueline Olender1, Norman H Lee2.   

Abstract

Alternative splicing, the process of removing introns and joining exons of pre-mRNA, is critical for growth, development, tissue homeostasis, and species diversity. Dysregulation of alternative splicing can initiate and drive disease. Aberrant alternative splicing has been shown to promote the "hallmarks of cancer" in both hematological and solid cancers. Of interest, recent work has focused on the role of alternative splicing in prostate cancer and prostate cancer health disparities. We will provide a review of prostate cancer health disparities involving the African American population, alternative RNA splicing, and alternative splicing in prostate cancer. Lastly, we will summarize our work on differential alternative splicing in prostate cancer disparities and its implications for disparate health outcomes and therapeutic targets.

Entities:  

Keywords:  Alternative splicing; Cancer disparities; Drug resistance; Prostate cancer

Mesh:

Year:  2019        PMID: 31576545      PMCID: PMC6777849          DOI: 10.1007/978-3-030-22254-3_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  133 in total

1.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

2.  Systems analysis of the prostate transcriptome in African-American men compared with European-American men.

Authors:  Gary Hardiman; Stephen J Savage; E Starr Hazard; Robert C Wilson; Sean M Courtney; Michael T Smith; Bruce W Hollis; Chanita Hughes Halbert; Sebastiano Gattoni-Celli
Journal:  Pharmacogenomics       Date:  2016-06-30       Impact factor: 2.533

Review 3.  Alternative splicing as a regulator of development and tissue identity.

Authors:  Francisco E Baralle; Jimena Giudice
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-10       Impact factor: 94.444

4.  Racial disparities in survival for patients with clinically localized prostate cancer adjusted for treatment effects.

Authors:  Mark D Tyson; Erik P Castle
Journal:  Mayo Clin Proc       Date:  2014-03       Impact factor: 7.616

5.  hnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L.

Authors:  Ngoc T Vu; Margaret A Park; Jacqueline C Shultz; Rachel W Goehe; L Alexis Hoeferlin; Michael D Shultz; Sarah A Smith; Kristen W Lynch; Charles E Chalfant
Journal:  J Biol Chem       Date:  2013-02-08       Impact factor: 5.157

6.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

7.  Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins.

Authors:  Stephanie C Huelga; Anthony Q Vu; Justin D Arnold; Tiffany Y Liang; Patrick P Liu; Bernice Y Yan; John Paul Donohue; Lily Shiue; Shawn Hoon; Sydney Brenner; Manuel Ares; Gene W Yeo
Journal:  Cell Rep       Date:  2012-02-23       Impact factor: 9.423

8.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.

Authors:  Es Rennel; E Waine; H Guan; Y Schüler; W Leenders; J Woolard; M Sugiono; D Gillatt; Es Kleinerman; Do Bates; Sj Harper
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

9.  Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

Authors:  A Mavrou; K Brakspear; M Hamdollah-Zadeh; G Damodaran; R Babaei-Jadidi; J Oxley; D A Gillatt; M R Ladomery; S J Harper; D O Bates; S Oltean
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

10.  Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.

Authors:  Samar Alsafadi; Alexandre Houy; Aude Battistella; Tatiana Popova; Michel Wassef; Emilie Henry; Franck Tirode; Angelos Constantinou; Sophie Piperno-Neumann; Sergio Roman-Roman; Martin Dutertre; Marc-Henri Stern
Journal:  Nat Commun       Date:  2016-02-04       Impact factor: 17.694

View more
  5 in total

1.  Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.

Authors:  Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano
Journal:  Cancer Health Disparities       Date:  2020

2.  Identification and Characterization of Alternatively Spliced Transcript Isoforms of IRX4 in Prostate Cancer.

Authors:  Achala Fernando; Chamikara Liyanage; Afshin Moradi; Panchadsaram Janaththani; Jyotsna Batra
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

3.  A repositioning screen using an FGFR2 splicing reporter reveals compounds that regulate epithelial-mesenchymal transitions and inhibit growth of prostate cancer xenografts.

Authors:  Ling Li; Jinxia Zheng; Megan Stevens; Sebastian Oltean
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-17       Impact factor: 6.698

4.  Gene expression analysis reveals a 5-gene signature for progression-free survival in prostate cancer.

Authors:  Zhuofan Mou; Jack Spencer; Bridget Knight; Joseph John; Paul McCullagh; John S McGrath; Lorna W Harries
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

5.  Identification of prognostic alternative splicing events in sarcoma.

Authors:  Hongshuai Li; Jie Yang; Guohui Yang; Jia Ren; Yu Meng; Peiyi Qi; Nan Wang
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.